MINNEAPOLIS, April 29, 2015 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to participate in the Bank of America Merrill Lynch 2015 Health Care Conference being held at The Encore at Wynn Hotel in Las Vegas.
James Hennen, Chief Financial Officer of Vascular Solutions, will present on Wednesday, May 13th at 5:00pm (PDT). To hear the live audio webcast, go to the investors page of the Company's web site http://www.vasc.com and click on the "Investor Conferences" icon a few minutes prior to start time to download any necessary software.
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of more than 90 products and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein specialists through its direct U.S. sales force and international independent distributor network.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2014 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, lack of sustained profitability, exposure to intellectual property claims, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, doing business in international markets, the availability of third party reimbursement, and actions by the FDA. The District Court grant of preliminary injunction may be stayed or overturned on appeal, and the granting of a preliminary injunction is not a determination of the ultimate merits of the litigation, which will be determined by the presentation of evidence at trial or in future dispositive motions.
For further information, connect to www.vasc.com.
CONTACT: Phil Nalbone, VP Vascular Solutions, Inc. (763) 656-4300 email@example.comSource:Vascular Solutions, Inc.